The Predictive Value of Pathologic Features in Pituitary Adenoma and Correlation with Pituitary Adenoma Recurrence
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The 2004 World Health Organization classification introduced atypical pituitary adenoma (aPA), which was equivocally defined as invasion with increased mitotic activity that had a Ki-67 labeling index (LI) greater than 3%, and extensive p53 immunoreactivity. However, aPAs that exhibit all of these features are rare and the predictive value for recurrence in pituitary adenomas (PAs) remains uncertain. Thus, we sought to characterize pathological features of PAs that correlated with recurrence. Methods: One hundred and sixty-seven cases of surgically resected PA or aPA were retrieved from 2011 to 2013 in Seoul St. Mary’s Hospital. Among them, 28 cases were confirmed to be recurrent, based on pathologic or radiologic examination. The pathologic characteristics including mitosis, invasion, Ki-67 LI and p53 immunoreactivity were analyzed in relation to recurrence. Results: Analysis of the pathologic features indicated that only Ki-67 LI over 3% was significantly associated with tumor recurrence (p = .02). The cases with at least one pathologic feature showed significantly higher recurrence rates (p < .01). Analysis indicated that cases with two pathologic features, Ki-67 LI over 3% and extensive p53 immunoreactivity 20% or more, were significantly associated with tumor recurrence (p < .01). Conclusions: Based on these results, PA tumor recurrence can be predicted by using mitosis, invasion, Ki-67 LI (3%), or extensive p53 immunoreactivity (≥ 20%). Assessment of these features is recommended for PA diagnosis for more accurate prediction of recurrence.
Abstract
Background: The 2004 World Health Organization classification introduced atypical pituitary adenoma (aPA), which was equivocally defined as invasion with increased mitotic activity that had a Ki-67 labeling index (LI) greater than 3%, and extensive p53 immunoreactivity. However, aPAs that exhibit all of these features are rare and the predictive value for recurrence in pituitary adenomas (PAs) remains uncertain. Thus, we sought to characterize pathological features of PAs that correlated with recurrence. Methods: One hundred and sixty-seven cases of surgically resected PA or aPA were retrieved from 2011 to 2013 in Seoul St. Mary’s Hospital. Among them, 28 cases were confirmed to be recurrent, based on pathologic or radiologic examination. The pathologic characteristics including mitosis, invasion, Ki-67 LI and p53 immunoreactivity were analyzed in relation to recurrence. Results: Analysis of the pathologic features indicated that only Ki-67 LI over 3% was significantly associated with tumor recurrence (p = .02). The cases with at least one pathologic feature showed significantly higher recurrence rates (p < .01). Analysis indicated that cases with two pathologic features, Ki-67 LI over 3% and extensive p53 immunoreactivity 20% or more, were significantly associated with tumor recurrence (p < .01). Conclusions: Based on these results, PA tumor recurrence can be predicted by using mitosis, invasion, Ki-67 LI (3%), or extensive p53 immunoreactivity (≥ 20%). Assessment of these features is recommended for PA diagnosis for more accurate prediction of recurrence.
참고문헌 (22)
- DeLellis RA, "World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs" (2004), IARC Press
- Kaltsas GA, "Clinical review: diagnosis and management of pituitary carcinomas", J Clin Endocrinol Metab, 90, pp.3089~3099 (2005)
- Fernandez A, "Prevalence of pituitary adenomas:a community-based, cross-sectional study in Banbury (Oxfordshire, UK)", Clin Endocrinol (Oxf), 72, pp.377~382 (2010)
- Daly AF, "High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium", J Clin Endocrinol Metab, 91, pp.4769~4775 (2006)
- Saeger W, "Pathohistological classification of pituitary tumors: 10years of experience with the German Pituitary Tumor Registry", Eur J Endocrinol, 156, pp.203~216 (2007)
- Al-Shraim M, "The 2004 World Health Organization classification of pituitary tumors: what is new?", Acta Neuropathol, 111, pp.1~7 (2006)
- Mete O, "Biomarkers of aggressive pituitary adenomas", J Mol Endocrinol, 49, pp.R69~R78 (2012)
- Yildirim AE, "Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas", Turk Neurosurg, 23, pp.226~231 (2013)
- Zada G, "Atypical pituitary adenomas: incidence, clinical characteristics, and implications", J Neurosurg, 114, pp.336~344 (2011)
- Lee EH, "Results of immunohistochemical staining of cell-cycle regulators: the prediction of recurrence of functioning pituitary adenoma", World Neurosurg, 81, pp.563~575 (2014)
- Alireza Sadeghipour, "Ki67 Labeling Correlated With Invasion But Not With Recurrence", Applied Immunohistochemistry & Molecular Morphology, pp.1~ (2016), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Hadzhiyanev A, "Evaluation of prognostic utility of MIB-1 and p53 expression in pituitary adenomas: correlations with clinical behaviour and follow-up results", Biotechnol Biotechnol Equip, 28, pp.502~507 (2014)
- Tortosa F, "Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal", Neurologia, 31, pp.97~105 (2016)
- Chiloiro S, "Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis", Neuroendocrinology, 101, pp.143~150 (2015)
- Szumilas M, "Explaining odds ratios", J Can Acad Child Adolesc Psychiatry, 19, pp.227~229 (2010)
- Figarella-Branger D, "The new WHO classification of human pituitary tumors: comments", Acta Neuropathol, 111, pp.71~72 (2006)
- Grossman AB, "The 2004 World Health Organization classification of pituitary tumors: is it clinically helpful?", Acta Neuropathol, 111, pp.76~77 (2006)
- Kleinschmidt-DeMasters BK, "Subtyping does matter in pituitary adenomas", Acta Neuropathol, 111, pp.84~85 (2006)
- Laws ER Jr, "The new WHO classification of pituitary tumors:highlights and areas of controversy", Acta Neuropathol, 111, pp.80~81 (2006)
- Maclean J, "Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma", carcinoma: variable clinical response in preliminary evaluation, 2014, pp.17, 530~538
- Matsuyama J, "Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables", Neurol Med Chir (Tokyo), 52, pp.563~569 (2012)
- Miermeister CP, "Histological criteria for atypical pituitary adenomas: data from the German pituitary adenoma registry suggests modifications", Acta Neuropathol Commun, 3, pp.50~ (2015)